QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Pertuzumab–Trastuzumab–Hyaluronidase Fixed-Dose Subcutaneous Combination Pharmacovigilance

Test your understanding of the concepts covered by Pertuzumab–Trastuzumab–Hyaluronidase Fixed-Dose Subcutaneous Combination: Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient receives the maintenance presentation as the first administration. Which classification best describes the primary pharmacovigilance concern?

A formulation-specific medication error involving incorrect treatment-phase selection A confirmed new cardiac toxicity of pertuzumab A local injection-site reaction regardless of clinical findings A pharmacokinetic failure that can be established without exposure information

Question 2 of 10 A case records only 'trastuzumab' although the patient received the fixed pertuzumab–trastuzumab combination. What is the principal data-quality consequence?

Pertuzumab exposure may disappear from the safety record, impairing product-level attribution and signal detection The case becomes more accurate because trastuzumab is the only active antibody The error affects only pharmacy inventory and not pharmacovigilance The event can still be fully analysed without reconstructing the administered product

Question 3 of 10 Why should cardiac and pregnancy-related signals be evaluated across the broader HER2 exposure context while retaining the specific formulation?

These risks may relate to shared HER2-directed biology, but formulation and exposure history remain important for accurate attribution The fixed-dose formulation eliminates the need to consider prior HER2 treatment Only the current product can contribute to cardiac or pregnancy outcomes Aggregate review should always replace product-specific review

Question 4 of 10 Which signal-detection interpretation is most appropriate if local injection reactions increase after adoption of the subcutaneous product?

It proves that a new HER2-class cardiac toxicity has emerged It may represent a formulation- or route-specific signal and should not automatically be labelled a class-wide antibody toxicity It should be ignored because local reactions are never reportable It demonstrates that intravenous administration was incorrectly recorded in every prior case

Question 5 of 10 Which information is most relevant when assessing possible HER2-directed cardiac dysfunction?

Only the injection site and needle size Baseline and serial LVEF, prior anthracycline exposure, cardiovascular comorbidity and previous HER2 therapy Only whether the patient experienced local erythema The exact time of the patient's most recent meal

Question 6 of 10 Why should the product be assessed at both pharmacodynamic and product-use levels in pharmacovigilance?

Because the antibodies have no established safety profile when administered together Because product-use factors can create distinct risks even when the underlying HER2-related pharmacology is unchanged Because subcutaneous administration eliminates all class-related risks Because pharmacodynamic assessment is relevant only to clinical trials

Question 7 of 10 Which data field is most important for distinguishing a local injection-site reaction from a systemic administration-related reaction?

The patient's postal address Whether symptoms were confined to the injection site or included systemic signs such as hypotension or bronchospasm The number of previous pharmacy visits The brand of chemotherapy premedication alone

Question 8 of 10 Which database design would best support pharmacovigilance for this product?

One generic trastuzumab entry used for all routes and formulations Separate product-dictionary entries with explicit loading or maintenance fields and structured route capture A database that stores only the reported adverse-event term A system that excludes medication errors from safety review

Question 9 of 10 Which follow-up question is most useful when investigating a suspected administration-related reaction?

Whether the symptoms occurred after loading or maintenance presentation and whether they were local or systemic Whether the patient had previously used an unrelated topical medicine Whether the product was stored in a different hospital building Whether the patient knew the generic names of both antibodies

Question 10 of 10 A patient develops neutropenic fever while receiving the fixed-dose combination with cytotoxic chemotherapy. Which approach is most appropriate?

Attribute the event automatically to the subcutaneous route Exclude the antibodies because neutropenia is a chemotherapy event by definition Assess the complete regimen, cycle timing, neutrophil nadir, infection evidence and supportive treatment Classify the event as an injection-site reaction unless hypotension is present

Knowledge Assessment: Pertuzumab–Trastuzumab–Hyaluronidase Fixed-Dose Subcutaneous Combination Pharmacovigilance

Cookie Settings